1. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  2. EGFR
  3. Nimotuzumab

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).

For research use only. We do not sell to patients.

CAS No. : 780758-10-3

Size Price Stock Quantity
1 mg USD 560 In-stock
5 mg USD 1950 In-stock
10 mg   Get quote  
50 mg   Get quote  

Get it by April 11 for select sizes. Order within 11 hrs 54 mins.

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC)[1][2].

Isotype

Human IgG1 kappa

Recommend Isotype Controls
Species

Humanized

In Vitro

Nimotuzumab (10 μg/mL; 24 hours) induces significant downregulation of CD16 on NK cells[1].
Nimotuzumab (10 μg/mL; 48 hours) induces the upregulation of PD-L1 molecule on DCs when co-cultured with the NK: DC: HNSCC cells[1].
The intrinsic properties of Nimotuzumab requires bivalent binding (i.e., binding with both antibody arms to two targets simultaneously) for stable attachment to cellular surface, which leads to Nimotuzumab selectively binding to cells that express moderate to high EGFR levels[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT03388372Biotech Pharmaceutical Co., Ltd.|Sun Yat-sen University
Glioblastoma
August 18, 2010Phase 2
NCT02011594Zhejiang University
Stage IV Esophageal Squamous Cell Carcinoma
January 2014Phase 2
NCT04949503Biotech Pharmaceutical Co., Ltd.
Locally Advanced Head and Neck Squamous Cell Carcinoma
October 8, 2021
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Nimotuzumab]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized EGFR vIII Protein, Human (HEK293, His, HY-P70189) can bind Nimotuzumab. The EC50 for this effect is 19 ng/mL.
Purity & Documentation

Purity: 96.80%

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Nimotuzumab
Cat. No.:
HY-P9968
Quantity:
MCE Japan Authorized Agent: